A groundbreaking new study published in the Journal of Autism and Developmental Disorders has found that cannabidiol (CBD) can offer meaningful therapeutic benefits for children and young adults diagnosed with autism spectrum disorder (ASD). The research highlights CBD’s potential to improve behavioral symptoms, ease anxiety, and enhance daily function in individuals with moderate to severe autism—without the psychoactive effects associated with THC.
The study observed 82 patients between the ages of 5 and 25 over a six-month period. Each participant was given CBD-rich cannabis oil, with a very low concentration of THC to avoid intoxication. Researchers carefully tracked the patients’ progress using validated behavioral assessment tools, parent-reported observations, and medical records. The results were consistent and encouraging: the majority of patients showed improvements in communication, reduced aggression, better emotional regulation, fewer repetitive behaviors, and improved sleep.
Parents and caregivers reported major improvements in quality of life. According to the study, about 80% of families noticed their child was calmer and more socially responsive. Around 60% said their child required fewer psychiatric medications such as antipsychotics or mood stabilizers after starting CBD. Importantly, there were no reports of major side effects. The most common minor reactions included drowsiness and changes in appetite, both of which subsided or were easily managed.
These findings add to a growing body of international research supporting CBD as a promising intervention for autism-related symptoms. A notable 2019 Israeli study involving 188 children also reported significant reductions in anxiety, restlessness, and communication difficulties with CBD use. Similar results have emerged from smaller-scale studies in Brazil and across Europe. However, this latest study is one of the most comprehensive U.S.-based evaluations to date.
While researchers stress that CBD is not a cure for autism, the cannabinoid appears to offer therapeutic value by interacting with the endocannabinoid system—an internal network that plays a role in mood, cognition, immune response, and neural communication. Some scientists believe that dysregulation in this system may contribute to symptoms of autism, making cannabinoids a logical area for further exploration.
Despite the positive outcomes, major barriers to CBD research remain. In the United States, CBD derived from cannabis (rather than hemp) remains a Schedule I substance under federal law, making large-scale clinical trials difficult to conduct and fund. Even hemp-derived CBD exists in a regulatory gray area, with varying rules from state to state and ongoing scrutiny from the Food and Drug Administration (FDA), which has yet to issue comprehensive guidance for its use in children.
Nonetheless, public demand for cannabinoid-based therapies continues to rise. Many parents of children with autism report turning to CBD after exhausting conventional pharmaceutical options—many of which come with severe side effects or limited effectiveness. In surveys conducted by autism advocacy organizations, a growing percentage of families say they’re interested in or already using cannabis-based products, often under the guidance of a medical professional.
The study’s authors emphasize the urgent need for expanded research, standardization of dosing protocols, and federal clarity on CBD’s legal status—particularly when used for pediatric care. With more than 1 in 36 children in the U.S. now diagnosed with autism, according to the CDC, there is increasing pressure on lawmakers and health officials to support novel, science-backed treatments that meet the needs of this growing population.
CBD’s non-intoxicating profile, relatively strong safety record, and ease of administration make it a promising option worth serious scientific and medical consideration. As more data becomes available, families and doctors alike will be better equipped to make informed decisions about incorporating CBD into autism treatment plans.
For more on topics like these, check this link out NEBRASKA STALLS MEDICAL MARIJUANA PROGRESS—AGAIN
